$70 Million Will Fund Tobacco Study Centers at Seven Universities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

BETHESDA, Md-Two components of the National Institutes of Health will spend about $70 million over 5 years to fund Transdisciplinary Tobacco Use Research Centers at seven universities. The first year’s grants from the National Cancer Institute and the National Institute on Drug Abuse (NIDA) will total $14.5 million. In addition, the Robert Wood Johnson Foundation has committed another $14 million over the 5 years.

BETHESDA, Md—Two components of the National Institutes of Health will spend about $70 million over 5 years to fund Transdisciplinary Tobacco Use Research Centers at seven universities. The first year’s grants from the National Cancer Institute and the National Institute on Drug Abuse (NIDA) will total $14.5 million. In addition, the Robert Wood Johnson Foundation has committed another $14 million over the 5 years.

The overall goal of the program is to find new ways to combat tobacco use and its consequences. Centers will be established at Brown University, the University of California, Irvine, the University of Southern California, Georgetown University, the University of Minnesota, the University of Wisconsin, and Yale University.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content